OVID Stock Overview
A biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Ovid Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.00 |
| 52 Week High | US$4.10 |
| 52 Week Low | US$0.68 |
| Beta | 0.29 |
| 1 Month Change | -4.85% |
| 3 Month Change | -9.99% |
| 1 Year Change | -70.87% |
| 3 Year Change | -70.53% |
| 5 Year Change | -78.33% |
| Change since IPO | -91.84% |
Recent News & Updates
Recent updates
Ovid Therapeutics: Data Readouts For Rare Epileptic Indications Late 2024
Apr 09We Think Ovid Therapeutics (NASDAQ:OVID) Can Afford To Drive Business Growth
Nov 10
Companies Like Ovid Therapeutics (NASDAQ:OVID) Are In A Position To Invest In Growth
Jun 27Here's Why We're Watching Ovid Therapeutics' (NASDAQ:OVID) Cash Burn Situation
Mar 13Is Ovid Therapeutics (NASDAQ:OVID) In A Good Position To Deliver On Growth Plans?
Sep 09Ovid Therapeutics GAAP EPS of -$0.21 beats by $0.04
Aug 09We Think Ovid Therapeutics (NASDAQ:OVID) Needs To Drive Business Growth Carefully
Jun 09Ovid Therapeutics: Good Entry Point For Investors
Jun 18Ovid Therapeutics appoints Jeff Rona as CFO
Jun 04Ovid Therapeutics Inc. (NASDAQ:OVID) Could Be Less Than A Year Away From Profitability
Apr 16Analysts Just Made A Captivating Upgrade To Their Ovid Therapeutics Inc. (NASDAQ:OVID) Forecasts
Mar 20Ovid Therapeutics Inc. (NASDAQ:OVID) Just Reported Full-Year Earnings And Analysts Are Lifting Their Estimates
Mar 18We're Keeping An Eye On Ovid Therapeutics' (NASDAQ:OVID) Cash Burn Rate
Mar 01Is Ovid Therapeutics Inc.'s (NASDAQ:OVID) Shareholder Ownership Skewed Towards Insiders?
Jan 25Revisiting Ovid Therapeutics
Jan 14Would Shareholders Who Purchased Ovid Therapeutics' (NASDAQ:OVID) Stock Three Years Be Happy With The Share price Today?
Dec 21Ovid Therapeutics misses goal in Angelman syndrome treatment
Dec 01Shareholder Returns
| OVID | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -3.0% | -3.6% | -2.4% |
| 1Y | -70.9% | -2.6% | 23.4% |
Return vs Industry: OVID underperformed the US Biotechs industry which returned -2.6% over the past year.
Return vs Market: OVID underperformed the US Market which returned 23.4% over the past year.
Price Volatility
| OVID volatility | |
|---|---|
| OVID Average Weekly Movement | 7.6% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: OVID has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: OVID's weekly volatility has decreased from 14% to 8% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 25 | Jeremy Levin | www.ovidrx.com |
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome.
Ovid Therapeutics Inc. Fundamentals Summary
| OVID fundamental statistics | |
|---|---|
| Market cap | US$70.95m |
| Earnings (TTM) | -US$32.50m |
| Revenue (TTM) | US$631.70k |
112.3x
P/S Ratio-2.2x
P/E RatioIs OVID overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OVID income statement (TTM) | |
|---|---|
| Revenue | US$631.70k |
| Cost of Revenue | US$0 |
| Gross Profit | US$631.70k |
| Other Expenses | US$33.13m |
| Earnings | -US$32.50m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.46 |
| Gross Margin | 100.00% |
| Net Profit Margin | -5,145.20% |
| Debt/Equity Ratio | 0% |
How did OVID perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 02:59 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Ovid Therapeutics Inc. is covered by 14 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kalpit Patel | B. Riley Securities, Inc. |
| Thomas Shrader | BTIG |
| Charles Duncan | Cantor Fitzgerald & Co. |